Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal Cancer
Anticancer Research · 2025
DOI: 10.21873/anticanres.17744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Noriko Wada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Oxaliplatin, Oxonic Acid, Tegafur, Rectal Neoplasms.
Abstract (Originalsprache)
BACKGROUND/AIM: Neoadjuvant chemoradiotherapy (CRT) is the standard treatment for locally advanced rectal adenocarcinoma, the optimal regimen remains unknown. For squamous cell carcinoma (SCC), 5-fluorouracil (5-FU) plus mitomycin C (MMC) with radiotherapy (RT) is commonly used; however, alternative medicines are needed for patients unable to receive MMC or those avoiding prolonged infusion. The combination of S-1 and oxaliplatin (SOX) with RT has been explored for rectal and anal cancer, but its efficacy and safety remain uncertain. This study retrospectively evaluated SOX + RT outcomes. PATIENTS AND METHODS: This single-center retrospective study analyzed 20 patients with anorectal adenocarcinoma and squamous cell carcinoma who received SOX + RT at Osaka University Hospital between March 2012 and June 2024. SOX+RT was administered as neoadjuvant or curative treatment. Tumor regression and adverse events were assessed per standard grading criteria. Survival analysis was performed using the Kaplan-Meier method. RESULTS: Among 20 evaluable cases, 14 were adenocarcinomas and 6 were SCCs. Twelve patients received the treatment as neoadjuvant therapy, while eight underwent it with curative intent. The local response rate was 60%, with all SCC cases achieving complete response. R0 resection was achieved in 83%, and anal preservation in 88%. The 3-year progression-free survival (PFS) rate was 39.2%, and overall survival (OS) was 70.6%, with SCC showing better PFS (80.0%) than adenocarcinoma (28.6%). Grade 3 adverse events occurred in 50%, but no treatment-related deaths were reported. CONCLUSION: SOX + RT was safe and effective, particularly for SCC, suggesting its potential as an alternative when standard therapy is not feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan.
- Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan taroh@cfs.med.osaka-u.ac.jp.
Zitieren
APA
Wada, N., Nishida, N., Takeda, M., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Eguchi, H., Doki, Y., & Satoh, T. (2025). Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17744
Vancouver
Wada N, Nishida N, Takeda M, Sekido Y, Hata T, Hamabe A, et al. Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal Cancer. Anticancer Research. 2025. doi:10.21873/anticanres.17744
BibTeX
@article{Wada2025,
author = {Wada, Noriko and Nishida, Naohiro and Takeda, Mitsunobu and Sekido, Yuki and Hata, Tsuyoshi and Hamabe, Atsushi and Ogino, Takayuki and Miyoshi, Norikatsu and Uemura, Mamoru and Eguchi, Hidetoshi and Doki, Yuichiro and Satoh, Taroh},
title = {Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal Cancer},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17744}
}
EUVIMED